子公司COMETIU支架国内注册未获批准，赛诺医疗“20cm”跌停

Core Viewpoint - Sino Medical (688108) experienced a significant decline in stock price, reaching a limit down of 20.01% to 20.15 CNY per share following the announcement of its product registration failure with the National Medical Products Administration (NMPA) [1] Group 1: Company Announcement - Sino Medical's subsidiary, Sino Shenchang Medical Technology Co., Ltd., received a notification from the NMPA on October 28 that its application for the COMETIU self-expanding intracranial drug-coated stent system was not approved for registration [1] - The company stated that the failure of the COMETIU stent's domestic registration will not have an immediate impact on its production and operations [1] - Sino Medical plans to continuously assess the long-term impact of the registration failure and will proceed with clinical, registration, and commercialization processes for the COMETIU stent in domestic, European, American, and global markets [1] Group 2: Future Plans - The company will make prudent operational arrangements based on objective conditions to ensure normal business operations and long-term sustainable development [1]